Mesoblast set for Asian launch
Monday, 16 February, 2009
Melbourne biotech Mesoblast has signed a collaborative program with Singapore’s Parkway Group Healthcare to trial its cartilage stem cell product RepliCart.
RepliCart is aimed at preventing or treating osteoarthritis of the knee, both in the elderly and following knee reconstruction surgery.
Last month, Mesoblast announced it was beginning Phase II trials of RepliCart in people under 40 who had undergone anterior cruciate ligament surgery
The agreement with Parkway Group Healthcare, which operates 15 private hospitals in Asia, involves a single-injection safety and efficacy trial at Parkway’s Clinical Centre of Excellence in Singapore.
Mesoblast said further trials were planned for additional clinical indications.
NSW Govt delivers foot-and-mouth vaccine to protect livestock
A biodegradable vaccine to protect livestock from foot-and-mouth disease has been developed as...
Scientists optimise delivery of mRNA to target cells
A highly versatile new method captures and attaches antibodies to the surface of mRNA-loaded...
'Anti-reward' brain network helps explain cocaine addiction
A new study identifies a specific 'anti-reward' network deep in the brain that undergoes...
